BioSyent Releases Financial Results for Third Quarter and First Nine Months of 2020
By Dr. Matthew Watson
MISSISSAUGA, Ontario, Nov. 26, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and nine months ended September 30, 2020. Key highlights include:
See original here:
BioSyent Releases Financial Results for Third Quarter and First Nine Months of 2020
Related Post
- Arbutus Announces 2021 Corporate Objectives and Provides Financial Update - January 25th, 2021
- Abeona Therapeutics Announces Successful Type B Meeting with FDA for Pivotal Phase 3 VIITAL™ Study of EB-101 in Recessive Dystrophic Epidermolysis... - January 25th, 2021
- Saniona received approximately USD $2.9 million (SEK 24.2 million) upfront payment in connection with Cadent Therapeutics transaction - January 25th, 2021
- aTyr Pharma Presents Findings Further Validating NRP2 as a Potential Regulator of Solid Tumor Progression - January 25th, 2021
- Cidara Therapeutics Announces Key Additions to its Board of Directors - January 25th, 2021
- BrightInsight Names Technology and Healthcare Leaders to Advisory Council - January 25th, 2021
- Albireo Announces U.S. FDA Acceptance of New Drug Application for Odevixibat - January 25th, 2021
- Better Choice Company Appoints Jenny Condon as Executive Vice President of Digital Sales - January 25th, 2021
- Vericel Announces Appointment of Joe Mara as Chief Financial Officer - January 25th, 2021
- Caladrius Biosciences Announces Participation in Upcoming Virtual Conferences in February 2021 - January 25th, 2021
- Golden Leaf Receives Approval to Extend Maturity of Convertible Debentures - January 25th, 2021
- Relief Therapeutics and Acer Therapeutics Sign Option Agreement for Exclusivity to Negotiate a Collaboration and License Agreement for the Worldwide... - January 25th, 2021
- Medexus Announces Renewal and Expansion of Canadian Distribution Agreement for NYDA® - January 25th, 2021
- Todos Medical Announces Strategic Investment by Yozma Group Korea - January 25th, 2021
- Neuropathix, Inc. CEO Recaps 2020 Advances and Potential Ahead - January 25th, 2021
- Information regarding the results of mandatory redemption of shares - January 25th, 2021
- Tauriga Sciences Inc. Completes the Package Design for Its Cherry Lime Rickey Flavor, Caffeine Infused Tauri-Gum Version - January 25th, 2021
- Eurobio Scientific: EXCEPTIONAL 2020 TURNOVER OF € 189 MILLION (+ 220%) - January 25th, 2021
- Valneva and Instituto Butantan Sign Final Agreement on Single-Shot Chikungunya Vaccine for Low and Middle Income Countries - January 25th, 2021
- GENFIT: Sweeping approval of OCEANEs buyback and amendments of terms - January 25th, 2021
- Codiak’s Versatile engEx™ Platform for Engineered Exosomes Published in the Journal Molecular Therapy - January 23rd, 2021
- CorMedix Inc. to Begin Trading on the Nasdaq Stock Exchange - January 23rd, 2021
- Auxly Announces Upsized Bought-Deal Public Offering to $17.5 Million - January 23rd, 2021
- Trishula Therapeutics Appoints Anil Singhal as Chief Executive Officer - January 23rd, 2021
- MDxHealth Launches Capital Increase and Provides Preliminary 2020 Financial Results - January 23rd, 2021
- DEINOVE strengthens its Business development team to deploy its partnering strategy - January 23rd, 2021
- Hollister Biosciences Inc. Announces an Increase in Private Placement to $6.5 Million - January 23rd, 2021
- Novavax Names Madelyn Caltabiano Senior Vice President, Global Program Management - January 23rd, 2021
- Zealand Pharma announces update to 2020 financial guidance - January 23rd, 2021
- Blood Sugar Premier – Does This Supplement Really Works? Ingredients & Blood Sugar Premier Reviews by Nuvectramedical - January 23rd, 2021
- Bespoke Extracts Announces $100K Investment From CEO and Addition of New Brand Ambassador, UFC Fighter Maryna Moroz - January 22nd, 2021
- Icosapent Ethyl Included in the Chinese Society of Cardiology (CSC) Updated Guidelines for Primary Prevention of Cardiovascular Diseases - January 22nd, 2021
- MDxHealth Successfully Completes a EUR 25.0 Million (USD 30.4 Million)(1) Capital Increase - January 22nd, 2021
- Ulcerative Colitis Phase II Study of GSK2831781 Discontinued - January 22nd, 2021
- Kiadis announces multiple abstracts related to its K-NK-cell therapy platform have been accepted for presentation at TCT, the Combined Transplantation... - January 22nd, 2021
- Immutep Quarterly Activities Report - January 22nd, 2021
- ONO Receives a Manufacturing and Marketing Approval of Adlumiz® (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in... - January 22nd, 2021
- Nicox Analyst Coverage Initiated by Edison Investment Research - January 22nd, 2021
- PCI Biotech to present at RNA Therapeutics Virtual Conference - January 22nd, 2021
- BioCryst Announces Approval of ORLADEYO™ (berotralstat) in Japan for the Prophylactic Treatment of Hereditary Angioedema - January 22nd, 2021
- Mydecine Innovations Group Included in First-Ever Psychedelics ETF - January 22nd, 2021
- aTyr Pharma to Present Poster Highlighting Research Approach for Identifying Receptor Targets for Extracellular tRNA Synthetases - January 22nd, 2021
- Equillium Announces Acceptance of Late-Breaking Abstract for Oral Presentation of Interim Data from EQUATE Study in acute GVHD at the 2021 TCT... - January 22nd, 2021
- Ten Leading BioPharma Companies Announce Formation of Accumulus Synergy to Develop Global Data Sharing Platform - January 22nd, 2021
- Report from the Extraordinary General Meeting of Immunicum AB (publ) on 22 January 2021 - January 22nd, 2021
- Albireo Recognizes International Alagille Syndrome Awareness Day 2021 - January 22nd, 2021
- Teligent Regains Compliance with Nasdaq Filing Requirements and Nasdaq Minimum Market Value Rule - January 22nd, 2021
- Cambium Networks Corporation Announces Fourth Quarter and Full Year 2020 Reporting Date - January 22nd, 2021
- Bioasis Announces Stock Option Grant - January 22nd, 2021
- Revive Therapeutics Included in First Psychedelic Exchange Traded Fund - January 22nd, 2021
- Better Choice Company Announces Strategic Investment of $2.7 Million, Co-Lead by Insiders and Management - January 19th, 2021
- TRACON Pharmaceuticals Announces Acceptance of the Envafolimab (KN035) NDA by the NMPA in China for Priority Review - January 19th, 2021
- Yield10 Bioscience Announces Achievement of Proof-of-Concept Milestone for Producing PHA Bioplastic in Field Grown Camelina Plants - January 19th, 2021
- XBiotech Announces Cerebrovascular Medical Advisory Board & Development of New Stroke Therapy - January 19th, 2021
- Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial - January 19th, 2021
- Vallon Pharmaceuticals Announces Presentation of ADAIR Pharmacokinetics and Pharmacodynamic Data at the Virtual 2021 APSARD Annual Meeting - January 19th, 2021
- Tarsus Pharmaceuticals, Inc. Appoints Bryan Wahl, MD, JD as General Counsel - January 19th, 2021
- Emerald Bioscience Launches Rebrand Including Name Change to Skye Bioscience - January 19th, 2021
- NexImmune Appoints Healthcare Innovator Grant Verstandig as New Board Member - January 19th, 2021
- Novan Provides Enrollment Update and Announces New Corporate Headquarters - January 19th, 2021
- Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences - January 19th, 2021
- Neuropathix, Inc. Announces Publication of Its Global PCT Patent for NPTX-204, a Novel Hops-Inspired Neuroprotectant - January 19th, 2021
- Bespoke Extracts Increases Conversion Price of Outstanding Discount Convertible Debentures - January 19th, 2021
- Lixte Biotechnology and City of Hope to Initiate Phase 1b Clinical Trial of Lixte’s Lead Compound LB-100 to Treat Small Cell Lung Cancer - January 19th, 2021
- Capricor Therapeutics Announces Publication Demonstrating Methods for Enhanced Potency of Cardiosphere-Derived Exosomes - January 19th, 2021
- Tauriga Sciences Inc. to Construct Product Showroom Within its New Corporate Headquarters - January 19th, 2021
- Theratechnologies Announces Closing of US$46 Million Bought-Deal Public Offering, Including Full Exercise of the Over-Allotment Option - January 19th, 2021
- VIRBAC:2020 annual revenue shows strong growth of +5.7% at constant exchange rates and scope (+3.2% at constant rates) - January 19th, 2021
- Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference - January 19th, 2021
- Agenus to Participate in B. Riley Securities' Oncology Investor Conference - January 19th, 2021
- IGM Biosciences Enters into Exclusive Licensing Agreement with Medivir for Birinapant - January 12th, 2021
- T2 Biosystems T2SARS-CoV-2™ Panel Proves Effective Amid Global Rise in Variants of the SARS-CoV-2 Virus - January 12th, 2021
- Theratechnologies Announces US$40 Million Bought-Deal Public Offering of Units - January 12th, 2021
- Qilian International Holding Group Limited Announces Pricing of Initial Public Offering - January 12th, 2021
- Adagene Announces Milestone of CAR-T Collaboration with the National Heart, Lung, and Blood Institute at the National Institutes of Health - January 12th, 2021
- Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common... - January 12th, 2021
- Addex to Present at the Baader Helvea Swiss Equities Conference - January 12th, 2021
- iosBio signs exclusive worldwide licensing agreement granting ImmunityBio rights to OraPro™ oral vaccine platform technology for COVID-19 - January 12th, 2021
- Bone Therapeutics treats first patient in ALLOB Phase IIb tibial fracture study - January 12th, 2021
- BetterLife Provides Shareholder Update and 2021 Product Development Roadmap - January 12th, 2021

Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research